Cabotamig Biosimilar – Anti-CDH17; T-cell surface glycoprotein CD3 epsilon chain mAb – Research Grade

Description of Cabotamig Biosimilar - Anti-CDH17; T-cell surface glycoprotein CD3 epsilon chain mAb - Research Grade

Introduction

Cabotamig Biosimilar – Anti-CDH17, T-cell surface glycoprotein CD3 epsilon chain mAb – Research Grade is a monoclonal antibody (mAb) that specifically targets the T-cell surface glycoprotein CD3 epsilon chain. This biosimilar is designed to mimic the structure and function of the original antibody, providing a more affordable and accessible option for researchers and clinicians.

Structure

Cabotamig Biosimilar is a recombinant humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each with a variable and constant region. The variable regions are responsible for binding to the target antigen, CD3 epsilon, while the constant regions determine the effector functions of the antibody.

Activity

The primary function of Cabotamig Biosimilar is to bind to the T-cell surface glycoprotein CD3 epsilon chain, which is found on the surface of T-cells. This binding triggers a cascade of events that ultimately leads to T-cell activation and proliferation. This is a crucial step in the immune response, as activated T-cells are able to recognize and eliminate infected or abnormal cells.

In addition to its role in T-cell activation, Cabotamig Biosimilar also has effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These functions allow the antibody to recruit other immune cells and proteins to aid in the destruction of target cells.

Application

Cabotamig Biosimilar has potential applications in both research and clinical settings. In research, it can be used as a tool to study the role of CD3 epsilon in T-cell activation and immune response. It can also be used to investigate the mechanisms of action of other antibodies targeting CD3 epsilon.

In the clinic, Cabotamig Biosimilar has shown promise as a potential therapeutic agent for various diseases. CD3 epsilon is a validated target for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. By targeting this protein, Cabotamig Biosimilar can potentially modulate the activity of T-cells and reduce the inflammation associated with these diseases.

In addition, CD3 epsilon is also overexpressed in certain types of cancer, making it a potential therapeutic target for cancer treatment. Cabotamig Biosimilar has shown promising results in preclinical studies as a potential treatment for solid tumors and hematological malignancies.

Conclusion

Cabotamig Biosimilar – Anti-CDH17, T-cell surface glycoprotein CD3 epsilon chain mAb – Research Grade is a recombinant monoclonal antibody that specifically targets CD3 epsilon, a protein found on the surface of T-cells. Its structure and activity mimic that of the original antibody, making it a valuable tool for research and a potential therapeutic agent for various diseases. With its potential to modulate T-cell activity and eliminate target cells, Cabotamig Biosimilar has the potential to improve the lives of patients suffering from autoimmune diseases and cancer.